Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone

European Journal of Clinical Pharmacology

Volumn 67, Issue 1, 2011, Pages 63-71

  Kummer, Oliver ^a   Hammann, Felix ^a   Moser, Claudine ^a   Schaller, Olivier ^b   Drewe, Jürgen ^a   Krähenbühl, Stephan ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Mundipharma Medical Company   (Switzerland)

Author keywords

Drug interactions; Ketoconazole; Oxycodone; Paroxetine; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; KETOCONAZOLE; OXYCODONE; PAROXETINE; PLACEBO;

ADULT; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; COLD PRESSOR TEST; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; EUPHORIA; HUMAN; HUMAN EXPERIMENT; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PRURITUS; PUPIL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANALGESICS, OPIOID; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; GENOTYPE; HUMANS; KETOCONAZOLE; MIOSIS; MORPHINANS; OXYCODONE; OXYMORPHONE; PAIN MEASUREMENT; PAROXETINE; PLACEBOS; YOUNG ADULT;

EID: 79151472756     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0893-3     Document Type: Article

References (44)

1. MP Davis J Varga D Dickerson D Walsh SB LeGrand R Lagman 2003 Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy Support Care Cancer 11 84 92 12560936
2. LS Nuutinen E Wuolijoki IT Pentikainen 1986 Diclofenac and oxycodone in treatment of postoperative pain: a double-blind trial Acta Anaesthesiol Scand 30 620 624 1:STN:280:DyaL2s7itleisA%3D%3D 10.1111/j.1399-6576.1986.tb02487.x 3544648
3. WC Parris BW Johnson Jr MK Croghan, et al. 1998 The use of controlled-release oxycodone for the treatment of chronic cancer pain: a randomized, double-blind study J Pain Symptom Manage 16 205 211 1:STN:280:DyaK1M%2FhvFyrug%3D%3D 10.1016/S0885-3924(98)00064-5 9803047
4. E Bruera M Belzile E Pituskin, et al. 1998 Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain J Clin Oncol 16 3222 3229 1:CAS:528:DyaK1cXmvFGrtLw%3D 9779695
5. GB Curtis GH Johnson P Clark, et al. 1999 Relative potency of controlled-release oxycodone and controlled-release morphine in a postoperative pain model Eur J Clin Pharmacol 55 425 429 1:CAS:528:DyaK1MXkslyrsrg%3D 10.1007/s002280050651 10492054
6. M Kirvela L Lindgren T Seppala KT Olkkola 1996 The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation J Clin Anesth 8 13 18 1:CAS:528:DyaK2sXjs1ShtLk%3D 10.1016/0952-8180(95)00092-5 8695073
7. B Lalovic B Phillips LL Risler W Howald DD Shen 2004 Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes Drug Metab Dispos 32 447 454 1:CAS:528: DC%2BD2cXis1ehuro%3D 10.1124/dmd.32.4.447 15039299
8. CE Inturrisi 2002 Clinical pharmacology of opioids for pain Clin J Pain 18 S3 S13 10.1097/00002508-200207001-00002 12479250
9. T Heiskanen KT Olkkola E Kalso 1998 Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone Clin Pharmacol Ther 64 603 611 1:CAS:528:DyaK1MXjslWhtA%3D%3D 10.1016/S0009-9236(98)90051-0 9871425
10. B Lalovic E Kharasch C Hoffer L Risler LY Liu-Chen DD Shen 2006 Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites Clin Pharmacol Ther 79 461 479 1:CAS:528:DC%2BD28XktVegsb4%3D 10.1016/j.clpt.2006.01.009 16678548
11. ST Zwisler TP Enggaard L Noehr-Jensen, et al. 2009 The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism Basic Clin Pharmacol Toxicol 104 335 344 1:CAS:528:DC%2BD1MXnt1Cltr4%3D 10.1111/j.1742-7843.2009.00378.x 19281600
12. ST Zwisler TP Enggaard S Mikkelsen K Brosen SH Sindrup 2010 Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia Acta Anaesthesiol Scand 54 232 240 1:CAS:528:DC%2BC3cXhvFWqsbc%3D 10.1111/j.1399-6576.2009.02104.x 19719813
13. NM Hagelberg TH Nieminen TI Saari M Neuvonen PJ Neuvonen K Laine KT Olkkola 2009 Voriconazole drastically increases exposure to oral oxycodone Eur J Clin Pharmacol 65 263 271 1:CAS:528:DC%2BD1MXitVyiu7Y%3D 10.1007/s00228-008- 0568-5 18836708
14. J Gronlund T Saari N Hagelberg IK Martikainen PJ Neuvonen KT Olkkola K Laine 2010 Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone J Clin Pharmacol 50 101 108 1:CAS:528:DC%2BC3cXhtFOgsb0%3D 10.1177/0091270009336444 19755414
15. TH Nieminen NM Hagelberg TI Saari, et al. 2009 Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone Anesthesiology 110 1371 1378 1:CAS:528:DC%2BD1MXmtFKntb8%3D 10.1097/ALN.0b013e31819faa54 19417618
16. S Laugesen TP Enggaard RS Pedersen SH Sindrup K Brosen 2005 Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol Clin Pharmacol Ther 77 312 323 1:CAS:528:DC%2BD2MXjtVyksbk%3D 10.1016/j.clpt.2004.11.002 15903129
17. B Müller K Zopf J Bachofer W Steimer 2003 Optimized strategy for rapid cytochrome P450 2D6 genotyping by real-time long PCR Clin Chem 49 1624 1631 10.1373/49.10.1624 14500587
18. M Wenk L Todesco S Krahenbuhl 2004 Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females Br J Clin Pharmacol 57 495 499 1:CAS:528:DC%2BD2cXjslGmsb0%3D 10.1111/j.1365-2125.2003.02049.x 15025748
19. M Neuvonen PJ Neuvonen 2008 Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatography- electrospray-tandem mass spectrometry Ther Drug Monit 30 333 340 1:CAS:528:DC%2BD1cXmsFyntrY%3D 10.1097/FTD.0b013e31816e2d4b 18520605
20. L Haegeli HP Brunner-La Rocca M Wenk M Pfisterer J Drewe S Krahenbuhl 2007 Sublingual administration of furosemide: new application of an old drug Br J Clin Pharmacol 64 804 809 1:CAS:528:DC%2BD1cXhtVKrtb8%3D 17875188
21. A Savitzky MJE Golay 2002 Smoothing and differentiation of data by simplified least squares procedures Anal Chem 36 1627 1639 10.1021/ac60214a047
22. E Eisenberg D Cohen E Lawental D Pud 2007 Personality traits and sensitivity to pain in male chronic opioid addicts J Opioid Manag 3 225 230 17957982
23. J Grönlund TI Saari NM Hagelberg PJ Neuvonen KT Olkkola K Laine 2010 Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone Br J Clin Pharmacol 70 78 87 10.1111/j.1365-2125.2010.03653.x 20642550
24. KK Lemberg TE Heiskanen M Neuvonen VK Kontinen PJ Neuvonen ML Dahl EA Kalso 2010 Does co-administration of paroxetine change oxycodone analgesia: an interaction study in chronic pain patients Scand J Pain 1 24 33 10.1016/j.sjpain.2009.09.003
25. AM Johnson 1989 An overview of the animal pharmacology of paroxetine Acta Psychiatr Scand Suppl 350 14 20 1:CAS:528:DyaK3cXjtVWisg%3D%3D 10.1111/j.1600-0447.1989.tb07161.x 2530769
26. M Larson S Folstein 2000 Selective serotonin reuptake inhibitor-induced mydriasis J Am Acad Child Adolesc Psychiatry 39 138 139 1:STN:280: DC%2BD3c7jvVOksQ%3D%3D 10.1097/00004583-200002000-00006 10673818
27. JA Schmitt WJ Riedel EF Vuurman M Kruizinga JG Ramaekers 2002 Modulation of the critical flicker fusion effects of serotonin reuptake inhibitors by concomitant pupillary changes Psychopharmacology (Berl) 160 381 386 1:CAS:528:DC%2BD38XktFGhsLY%3D 10.1007/s00213-001-0993-y
28. RD Knaggs IM Crighton TF Cobby AJ Fletcher GJ Hobbs 2004 The pupillary effects of intravenous morphine, codeine, and tramadol in volunteers Anesth Analg 99 108 112 1:CAS:528:DC%2BD2cXkvVGjs7Y%3D 10.1213/01.ANE.0000116924.16535. BA 15281513
29. RB Murray MW Adler AD Korczyn 1983 The pupillary effects of opioids Life Sci 33 495 509 1:CAS:528:DyaL3sXks1eks7k%3D 10.1016/0024-3205(83)90123-6 6136886
30. HK Lee SC Wang 1975 Mechanism of morphine-induced miosis in the dog J Pharmacol Exp Ther 192 415 431 1:CAS:528:DyaE2MXhtlejsr4%3D 1117427
31. MR Prow KF Martin DJ Heal 1996 8-OH-DPAT-induced mydriasis in mice: a pharmacological characterisation Eur J Pharmacol 317 21 28 1:CAS:528: DyaK28XntlOjt74%3D 10.1016/S0014-2999(96)00693-0 8982715
32. EN Duman M Kesim M Kadioglu E Yaris NI Kalyoncu N Erciyes 2004 Possible involvement of opioidergic and serotonergic mechanisms in antinociceptive effect of paroxetine in acute pain J Pharmacol Sci 94 161 165 1:CAS:528: DC%2BD2cXhvVCgtrk%3D 10.1254/jphs.94.161 14978354
33. M Kesim EN Duman M Kadioglu E Yaris NI Kalyoncu N Erciyes 2005 The different roles of 5-HT(2) and 5-HT(3) receptors on antinociceptive effect of paroxetine in chemical stimuli in mice J Pharmacol Sci 97 61 66 1:CAS:528:DC%2BD2MXhtVGgsbk%3D 10.1254/jphs.FP0040153 15655293
34. VP Singh NK Jain SK Kulkarni 2001 On the antinociceptive effect of fluoxetine, a selective serotonin reuptake inhibitor Brain Res 915 218 226 1:CAS:528:DC%2BD3MXnsVSnuro%3D 10.1016/S0006-8993(01)02854-2 11595211
35. MK Erjavec BA Coda Q Nguyen G Donaldson L Risler DD Shen 2000 Morphine-fluoxetine interactions in healthy volunteers: analgesia and side effects J Clin Pharmacol 40 1286 1295 1:CAS:528:DC%2BD3cXnvV2msbw%3D 11075315
36. NC Gordon PH Heller RW Gear JD Levine 1994 Interactions between fluoxetine and opiate analgesia for postoperative dental pain Pain 58 85 88 1:STN:280:DyaK2M%2FmtV2ntA%3D%3D 10.1016/0304-3959(94)90187-2 7970842
37. A Ferrari CP Coccia A Bertolini E Sternieri 2004 Methadone-metabolism, pharmacokinetics and interactions Pharmacol Res 50 551 559 1:CAS:528: DC%2BD2cXovVyqsr8%3D 10.1016/j.phrs.2004.05.002 15501692
38. T Tateishi Y Krivoruk YF Ueng AJ Wood FP Guengerich M Wood 1996 Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation Anesth Analg 82 167 172 1:CAS:528:DyaK28XhtFGkurs%3D 10.1097/00000539-199601000-00031 8712396
39. K Kobayashi T Yamamoto K Chiba M Tani N Shimada T Ishizaki Y Kuroiwa 1998 Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4 Drug Metab Dispos 26 818 821 1:CAS:528:DyaK1cXlsVSqsL0%3D 9698298
40. YT Liu HP Hao CX Liu GJ Wang HG Xie 2007 Drugs as CYP3A probes, inducers, and inhibitors Drug Metab Rev 39 699 721 1:CAS:528:DC%2BD2sXhtlyitbnI 10.1080/03602530701690374 18058330
41. B Link M Haschke N Grignaschi M Bodmer YZ Aschmann M Wenk S Krahenbuhl 2008 Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping Br J Clin Pharmacol 66 473 484 1:CAS:528:DC%2BD1cXhtlSgur%2FL 10.1111/j.1365-2125.2008.03201.x 18537963
42. J Kirchheiner H Schmidt M Tzvetkov JT Keulen J Lotsch I Roots J Brockmoller 2007 Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication Pharmacogenomics J 7 257 265 1:CAS:528:DC%2BD2sXotlSnt78%3D 10.1038/sj.tpj.6500406 16819548
43. G Koren J Cairns D Chitayat A Gaedigk SJ Leeder 2006 Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother Lancet 368 704 10.1016/S0140-6736(06)69255-6 16920476
44. UM Stamer F Stuber T Muders F Musshoff 2008 Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication Anesth Analg 107 926 929 10.1213/ane.0b013e31817b796e 18713907